Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

5.630 +0.630 (+12.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm
From Schall Law Firm
Via Business Wire
Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views
Via Benzinga
Topics Earnings
Exposures Financial
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Dow Dips 250 Points; US Weekly Jobless Claims Surge
Via Benzinga
Topics Stocks
Exposures US Equities
WBD Stock Pops as Warner Bros. Considers Streaming Spinoff
Warner Bros. stock is rising on Thursday as reports about a potential spinoff of its streaming division embolden WBD investors. 
Via InvestorPlace
Agenus Loses More Than 50% Value On Thursday - Here's Why
Agenus shares drop amid FDA's feedback on its immunotherapy combo botensilimab and balstilimab for colorectal cancer. The FDA advised against accelerated approval, citing concerns about survival... 
Via Benzinga
Exposures Product Safety
Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
NKGen Biotech stock is up Thursday as NKGN holders react to plans for a presentation at the Alzheimer’s Association International Conference. 
Via InvestorPlace
Why Is Agenus (AGEN) Stock Down 55% Today?
Agenus stock is down on Thursday after the company provided AGEN investors with an update on a Phase 2 clinical trial meeting. 
Via InvestorPlace
US Stocks Edge Higher; D.R. Horton Posts Upbeat Earnings
Via Benzinga
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
From Agenus Inc.
Via Business Wire
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
From Agenus Inc.
Via Business Wire
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
From Agenus Inc.
Via Business Wire
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
From Agenus Inc.
Via Business Wire
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
From Agenus
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Agenus Announces Virtual Annual Shareholders Meeting
From Agenus Inc.
Via Business Wire
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended. 
Via InvestorPlace
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
From Agenus Inc.
Via Business Wire
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
From Agenus Inc.
Via Business Wire
3 Magnificent Growth Stocks to Buy Hand Over Fist
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
From Agenus Inc.
Via Business Wire
Agenus (AGEN) Q1 2024 Earnings Call Transcript
AGEN earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q1 2024
AGEN stock results show that Agenus missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Agenus Reports First Quarter 2024 Results
From Agenus Inc.
Via Business Wire
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Agenus Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.